News
Speakers:
Colleen Donder, CADTH
Dr. Dzung X. Vo, BC Children’s Hospital and University of British Columbia
Due to the prevalence and burden of chronic pain, and the associated opioid crisis in our country, health professionals are looking for non-pharmacological treatment options to recommend to their patients. Join CADTH for a webinar on the c...
Today, CADTH has issued final recommendations for:
Daratumumab (Darzalex) in combination with bortezomib, melphalan and prednisone for newly diagnosed multiple myeloma
Funding Request: In combination with bortezomib, melphalan and prednisone, for the treatment of patients with newly diagnosed multiple myeloma who are not suitable for autologou...
CADTH has received the following notice(s) of pending drug submission(s).
Brand name
Mayzent
TBC
Generic name
siponimod
brolucizumab
Manufacturer
Novartis Pharmaceuticals Canada Inc.
Novartis Pharmaceuticals Canada Inc.
Indication(s)
For the treatment of patient with secondary progressive...
A document related to the project entitled Drugs for Osteoporosis is now available for feedback from all interested stakeholders.
Project
Call for Feedback
Feedback Due By
Drugs for Osteoporosis
2019-08-28
2019-09-12
Consultation Document
Product Type
Submit Stakeholder Feedback
Included Stu...
See CADTH Pharmaceutical Reviews Update — Issue 10 for important news and information regarding CADTH’s drug review programs. Highlights from this issue include:
an extension of the feedback period on the ongoing consultations
an updated procedure for implementation-phase clinical panels
the upcoming announcement of a pilot p...
